JAK-STAT Signaling and Disease Pathogenesis in RA and IBD
| Overview / Abstract: |
With increasing evidence showing that the Janus kinase (JAK) inhibition can be used as a target for certain immune-mediated diseases, this activity reviews the benefits and safety concerns gastroenterologists and rheumatologists need to consider. |
|
Expiration |
Nov 29, 2019 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
|
Format |
Webinar / Webcast / Video |
|
Credits / Hours |
0.25 |
|
Accreditation |
ACCME, CME, CE |
|
Presenters / Authors / Faculty |
Allan Gibofsky, MD, JD, MACR, FACP, FCLM; Bruce E. Sands, MD, MS |
|
Sponsors / Supporters / Grant Providers |
This activity is jointly provided by Global Education Group and Integritas Communications. Based on a live symposium supported by an educational grant from Gilead Sciences, Inc. |
|
Keywords / Search Terms |
Integritas Communications gastroenterologists, rheumatologists, CME, CE, JAK Free CE CME |
|